Journal
NEUROLOGICAL SCIENCES
Volume 37, Issue 1, Pages 57-65Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-015-2357-0
Keywords
Melatonin; Neurodegenerative diseases; Alzheimer disease; Parkinson disease; Sleep; REM sleep behavior disorder
Categories
Funding
- Natural Science Foundation of China (NSFC) [81273600, 30970659]
- Natural Science Foundation of Hebei Province [H2013206147, C2011206145]
- Hebei Key Technology Support Program [12276405D]
- Department of Health of Hebei Province [20090047]
- China Rehabilitation Research Center optional research project [2014-7]
Ask authors/readers for more resources
The purpose of this work is to investigate the efficacy of exogenous melatonin in the treatment of sleep disorders in patients with neurodegenerative disease. We searched Pubmed, the Cochrane Library, and ClinicalTrials.gov, from inception to July 2015. We included randomized clinical trials (RCTs) that compared melatonin with placebo and that had the primary aim of improving sleep in people with neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). We pooled data with the weighted mean difference in sleep outcomes. To assess heterogeneity in results of individual studies, we used Cochran's Q statistic and the I 2 statistic. 9 RCTs were included in this research. We found that the treatment with exogenous melatonin has positive effects on sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) in PD patients (MD: 4.20, 95 % CI: 0.92-7.48; P = 0.01), and by changes in PSQI component 4 in AD patients (MD: 0.67, 95 % CI: 0.04-1.30; P = 0.04), but not on objective sleep outcomes in both AD and PD patients. Treatment with melatonin effectively improved the clinical and neurophysiological aspects of rapid eye movement (REM) sleep behavior disorder (RBD), especially elderly individuals with underlying neurodegenerative disorders. This meta-analysis provided some evidence that melatonin improves sleep quality in patients with AD and PD, and melatonin can be considered as a possible sole or add-on therapy in neurodegenerative disorders patients with RBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available